ATL146e decreases H-R–induced pulmonary inflammation
| Cells (105) . | Normoxia . | Hypoxia-reoxygenation . | ||
|---|---|---|---|---|
| (a) NY1DD vehicle (n = 8) . | (b) NY1DD ATL146e (n = 8) . | (c) NY1DD vehicle (n = 6) . | (d) NY1DD ATL146e (n = 6) . | |
| iNKT | 0.5 (0.04) | 0.29 (0.03)* | 1.1 (0.2)* | 0.26 (0.05)** |
| NK | 4.2 (0.5) | 1.2 (0.3)* | 3.0 (0.6) | 1.6 (0.2) |
| CD4 | 3.0 (0.2) | 1.0 (0.2)* | 3.3 (1.0) | 0.5 (0.1)** |
| CD8 | 2.3 (0.4) | 0.9 (0.1)* | 3.1 (0.9) | 0.5 (0.1)** |
| PMNs | 2.3 (0.3) | 0.4 (0.1)* | 9.8 (4.1)* | 1.1 (0.5)** |
| EBD | 117.5 (7.9) | 36.7 (6.7)* | 191.9 (19.3)* | 53.1 (12.2)** |
| Cells (105) . | Normoxia . | Hypoxia-reoxygenation . | ||
|---|---|---|---|---|
| (a) NY1DD vehicle (n = 8) . | (b) NY1DD ATL146e (n = 8) . | (c) NY1DD vehicle (n = 6) . | (d) NY1DD ATL146e (n = 6) . | |
| iNKT | 0.5 (0.04) | 0.29 (0.03)* | 1.1 (0.2)* | 0.26 (0.05)** |
| NK | 4.2 (0.5) | 1.2 (0.3)* | 3.0 (0.6) | 1.6 (0.2) |
| CD4 | 3.0 (0.2) | 1.0 (0.2)* | 3.3 (1.0) | 0.5 (0.1)** |
| CD8 | 2.3 (0.4) | 0.9 (0.1)* | 3.1 (0.9) | 0.5 (0.1)** |
| PMNs | 2.3 (0.3) | 0.4 (0.1)* | 9.8 (4.1)* | 1.1 (0.5)** |
| EBD | 117.5 (7.9) | 36.7 (6.7)* | 191.9 (19.3)* | 53.1 (12.2)** |
NY1DD mice were subjected to 3 hours of hypoxia (8% O2) followed by 18 hours of reoxygenation (room air). NY1DD mice subjected to hypoxia-reoxygenation displayed significant increases in pulmonary iNKT cells and polymorphonuclear leukocytes compared to normoxic controls as well as increased vascular permeability (c vs a). Three hours into reoxygenation Alzet minipumps were implanted to infuse vehicle or ATL146e (10 ng/kg/minute). NY1DD mice treated with ATL146e during reoxygenation displayed significantly decreased pulmonary leukocytes and improved vascular permeability (d vs c). Data represents means ± SEM and were analyzed by 1-way ANOVA with Neuman-Keuls posttesting.
P < .05 (vs a).
P < .05 (vs c).